Related Experiment Video

Updated: Apr 12, 2026

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

10.1K

Growth Factor Receptor Fusions Predict Therapeutic Sensitivity

Manmeet S Ahluwalia1, Jeremy N Rich2

  • 1Burkhardt Brain Tumor Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio. ahluwam@ccf.org.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 22, 2015
PubMed

Insights

Growth factor receptor fusions, unlike overexpression, indicate strong tumor dependence on receptor activity. This finding identifies predictive biomarkers for targeted cancer therapies and precise oncology treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Dysregulated growth factor pathways are hallmarks of many cancers, driving tumor progression.
  • Targeting growth factor receptors is a common cancer therapy strategy, but often limited by receptor overexpression or amplification.
  • Tumors with growth factor receptor fusions show a distinct dependency on receptor signaling.

Purpose of the Study:

  • To investigate the differential impact of growth factor receptor alterations (overexpression/amplification vs. fusions) on tumor cell dependence.
  • To identify specific molecular alterations that serve as predictive biomarkers for targeted cancer therapies.
  • To inform the development of precise oncology treatment strategies based on tumor molecular profiles.

Main Methods:

  • Analysis of tumor molecular data, including gene expression and genomic alterations.
  • Functional studies assessing the impact of receptor fusions and overexpression on signaling pathways.
  • Correlation of specific receptor alterations with patient response to targeted therapies.

Main Results:

  • Tumors with growth factor receptor fusions exhibit a heightened dependence on the aberrant receptor's activity.
  • Receptor overexpression or amplification, while common, does not consistently predict sensitivity to receptor-targeted agents.
  • Growth factor receptor fusions serve as potent predictive biomarkers for patient response.

Conclusions:

  • Growth factor receptor fusions represent a distinct oncogenic mechanism conferring exquisite pathway dependence.
  • Identifying receptor fusions is crucial for selecting patients who will benefit from specific targeted therapies.
  • This highlights the importance of molecular profiling for guiding precise oncology treatment decisions.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K